SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-17-057220
Filing Date
2017-10-17
Accepted
2017-10-17 19:19:27
Documents
2
Period of Report
2017-10-13

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4480
2 POA DOCUMENT poa.txt EX-24.4_748544 3267
  Complete submission text file 0001209191-17-057220.txt   9141
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Issuer) CIK: 0001382911 (see all company filings)

IRS No.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address 3344 NORTH TORREY PINES COURT SUITE 200 LA JOLLA CA 92037
Business Address
Keyes Jason A (Reporting) CIK: 0001678152 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33415 | Film No.: 171141610